You are here

Perimenopause is a time of “Endogenous Ovarian Hyperstimulation”

Perimenopausal endogenous ovarian hyper-stimulation” is the exact opposite of “The Myth of the Shriveling Ovary”: High estrogen levels during perimenopause, coupled with characteristically intermittent ovulation, can explain much of the misery of perimenopause.

Type: 
Articles
Life Phase: 
Perimenopause

The Death of Hormone Replacement Therapy — Why and how to use Ovarian Hormone Therapy

Dr. Jerilynn C. Prior, Scientific Director of the Centre for Menstrual Cycle and Ovulation Research, has never advocated the use of hormones as an ongoing "replacement" for menopause. She does not feel that menopause is a medical condition that needs to be "fixed". Rather it is a normal stage of life. She strongly advocates use of new term for the few women who do need therapy in menopause. The new term is: Ovarian Hormone Therapy.

Type: 
Articles
Life Phase: 
Menopause

What the Women’s Health Initiative Results Mean for Breast Cancer Survivors

In July 2002 a large, randomized control trial called the Women’s Health Initiative was stopped three years early with the conclusion that Estrogen plus Progestin (E+P) is, on balance, not an effective preventative medication for healthy menopausal women. The results of this trial have surprised both doctors and the general public, because they have shown that E+P does not prevent heart disease and causes breast cancer (1). We believe there are several changes in concepts about menopausal hormone therapy that are important for breast cancer survivors.

Type: 
Articles
Life Phase: 
Perimenopause, Menopause

Daily Menopause Diary

This diary is for women who have gone at least 12 months without a menstrual period
You will need the free Adobe Acrobat Reader in order to read and print them. If you don't already have this program, you can download it for free

Type: 
Diary
Life Phase: 
Menopause

Estrogen Deficiency: The Wrong Idea About Menopause

The largest and best-controlled trial testing whether hormone “replacement” therapy prevented heart disease was stopped three years early in July 2002. The Women’s Heath Initiative (WHI) study included over 16,600 healthy menopausal women without symptoms. These women were randomized to daily conjugated equine estrogen (Premarin, 0.625 mg) plus medroxyprogesterone (Provera, 2.5 mg) or an identical placebo. Hormone therapy increased breast cancer significantly (by 26% over placebo) and caused higher rates of heart attacks (29%), strokes (41%) and blood clots (211%). These risks outweighed this therapy’s significant benefits in preventing osteoporotic fractures of the hip (decreased by 34%) and colon cancer (decreased by 36%).
Since July 2002,hundreds of talk shows and editorials across North America have discussed these results. Many doctors and medical groups have offered criticisms. However, no one has yet identified what I believe is most important.

Type: 
Articles
Life Phase: 
Menopause

Pages

Estrogen’s Storm Season: Stories of Perimenopause

Estrogen's Storm Season

by Dr. Jerilynn C Prior

New second edition available

Estrogen’s Storm Season is now available in BOTH print and eBook (Mobi and ePUB) versions!

All royalties are recieved in our Endowment fund (overseen by UBC) and support CeMCOR's research and future.

It is full of lively, realistic stories with which women can relate and evidence-based, empowering perimenopause information. It was a finalist in 2006 for the Independent Publisher Book Award in Health.

Purchase your ebook copy via our Amazon Kindle or
Google Play storefronts!

Paperback copies (with updated insert) still available here.

Join a Study:

Get Involved

Volunteer research participants are the heart of all CeMCOR research. Participants are invited to provide feedback on study processes, to learn their own results and at the end of a study, be the first to hear what the whole study found. Please become a CeMCOR research participant—you can contribute to improving the scientific information available for daughters, friends and the wider world of women.